# SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Source: https://onco.cc/trials/nct06627712/  
OnCo record `nct06627712` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in triple-negative breast cancer, run by West China Hospital, now recruiting.

## Summary

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC is a phase 3, randomised interventional study registered as NCT06627712 by West China Hospital, with a registry enrolment figure of 318 participants, started 2024-11-01 and due to reach its primary completion in 2029-11-01. Interventions recorded: SBRT+PD-1 Inhibitor + Chemotherapy; PD-1 Inhibitor + Chemotherapy. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically or cytologically confirmed TNBC (ER-, PR-, HER2-)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06627712
- Phase: 3
- Setting: Stereotactic Body Radiotherapy (SBRT) Combined With PD-1 Inhibitor and Chemotherapy in Early-stage Treatment-naive Triple-negative Breast Cancer Patients: A Multicenter Phase III Clinical Study
- Sponsor: West China Hospital
- Enrolled: 318

## Sources

- ClinicalTrials.gov NCT06627712: https://clinicaltrials.gov/study/NCT06627712

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06627712.json